Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Cancer Research and Therapeutics|September 15, 2020
Long-term survival of a patient with programmed death ligand 1-negative lung adenocarcinoma and oligoprogressive disease treated with nivolumab and stereotactic body radiation therapyMiguel J Sotelo, Santiago Cabezas-Camarero, Alejandro Riquelme, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 6, 2006
New target-based agents involve new clinical trial designsCoralia Bueno Muíño, José Angel García-Sáenz, Sara López Tarruella, et al.
Cancers|February 15, 2022
HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic SubtypingCoralia Bueno Muiño, Miguel Martín, María Del Monte-Millán, et al.
European Journal of Case Reports in Internal Medicine|February 23, 2023
A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by <i>Enterococcus faecalis</i>Francisco Javier Teigell-Muñoz, María Mateos-González, Elsa Bernal Hertfelder, et al.
Thrombosis Research|June 24, 2026
Prevalence and clinical outcomes associated with proximal deep vein thrombosis at hospital admission detected by bedside ultrasound in patients hospitalized in a medical oncology ward: An exploratory prospective studyFrancisco Javier Teigell Muñoz, María García-Ferrón, María Mateos-González, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 25, 2006
Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapiesJavier Puente Vázquez, Sara López-Tarruella Cobo, José A García-Sáenz, et al.
Breast Cancer Research and Treatment|January 2, 2017
Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancerIsabel Echavarria, Mónica Granja, Coralia Bueno, et al.
Oncotarget|February 9, 2018
Prognostic value of quantitative ctDNA levels in non small cell lung cancer patientsMariano Provencio, María Torrente, Virginia Calvo, et al.
The Oncologist|April 27, 2019
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast CancerEva Ciruelos, María Apellániz-Ruiz, Blanca Cantos, et al.
Breast Cancer Research and Treatment|May 4, 2024
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohortRodrigo Sánchez-Bayona, Alfonso Lopez de Sa, Yolanda Jerez Gilarranz, et al.
Pageof 2